XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.1
License Agreements - Lilly (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 148 Months Ended
Mar. 31, 2022
May 31, 2019
Dec. 31, 2009
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2022
Mar. 31, 2016
License agreements              
Research and Development Expense       $ 353,373 $ 306,896    
Revenues       733,235 604,718    
OLUMIANT Royalty Revenues              
License agreements              
Revenues       48,064 32,258    
Eli Lilly | Development Milestones              
License agreements              
Amount recognized and received for the achievement of a predefined milestone           $ 149,000  
Eli Lilly | Development Milestones | Maximum              
License agreements              
Upfront and immediate milestone payment to be received under license agreement     $ 150,000        
Eli Lilly | Regulatory Milestones              
License agreements              
Amount recognized and received for the achievement of a predefined milestone           265,000  
Eli Lilly | Regulatory Milestones | Maximum              
License agreements              
Upfront and immediate milestone payment to be received under license agreement     365,000        
Eli Lilly | Commercialization Milestones              
License agreements              
Amount recognized and received for the achievement of a predefined milestone           $ 50,000  
Eli Lilly | Commercialization Milestones | Maximum              
License agreements              
Upfront and immediate milestone payment to be received under license agreement     $ 150,000        
Eli Lilly | OLUMIANT Royalty Revenues | Non-U.S.              
License agreements              
Revenues       $ 48,000 $ 32,300    
Eli Lilly | GVHD              
License agreements              
Additional milestone payments under the license agreement             $ 40,000
Eli Lilly | GVHD | Regulatory Milestones              
License agreements              
Milestone payment made under license agreement   $ 20,000          
Eli Lilly | GVHD | Regulatory Milestones | Europe              
License agreements              
Milestone payment made under license agreement $ 20,000